Institutional Investor (March 12)
“February was a disaster for many biopharma, life sciences, and other health care hedge funds. Most lost money, several by double-digit rates, and as a result were in the red heading into March.” Whether the Trump administration will “slow down or pause the approval process for drugs currently in development” is making investors “jittery.” On top of that, “the stock market’s general volatility and sell-off have been especially rough on fledgling companies with little or no revenue and earnings — including this sector — exacerbating investor concerns.”
Tags: Approval process, Biopharma, Development, Disaster, Drugs, February, Health care, Hedge funds, Investors, Jjittery, Life sciences, Sell-off, Stock market, Trump administration, Volatility
